A longitudinal study of children identifies antibody Fc-mediated functions and antigen targets of immunity to Plasmodium vivax malaria
February 26, 2026
Plasmodium vivax is the most widespread cause of malaria with a high burden of disease. Progress in reducing the global malaria…
Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial
February 11, 2026
Background Shorter courses of primaquine and single-dose tafenoquine have potential to improve the prevention of recurrent Plasmodium vivax infections, but there are…
Strengthening the health systems at national level for malaria elimination in the Greater Mekong Subregion countries: a qualitative study
February 5, 2026
Background: Countries in the Greater Mekong Subregion (GMS) have committed to eliminating malaria by 2030. The success of a national malaria…
Projected impacts of climate change on malaria in Africa
January 28, 2026
The implications of climate change for malaria eradication this century remain poorly resolved1,2. Many studies focus on parasite and vector…
PTRAMP, CSS and Ripr form a conserved complex required for merozoite invasion of Plasmodium species into erythrocytes
January 26, 2026
Invasion of erythrocytes by members of the Plasmodium genus is an essential step of the parasite lifecycle, orchestrated by numerous host-parasite interactions….
The role of the spleen in red blood cell loss caused by malaria: A mathematical model
January 12, 2026
The human spleen significantly influences red blood cell (RBC) dynamics due to its ability to retain and/or remove RBCs from…
Spatiotemporal trends in P. falciparum malaria and identification of high-risk villages in Eastern Myanmar: an 8-year observational study
December 11, 2025
One barrier to achieving Plasmodium falciparum elimination is the persistence of villages where transmission remains high. While targeted interventions can effectively reduce…
Adjunctive ruxolitinib attenuates inflammation and enhances immunity in volunteers experimentally infected with Plasmodium falciparum
November 26, 2025
Inhibiting the inflammatory response to malaria offers a promising strategy to improve clinical outcomes and overcome immunoregulatory barriers that hinder…
Beyond malaria: can intermittent preventive treatment with sulphadoxine-pyrimethamine reduce the number of small vulnerable newborns globally?
November 17, 2025
Efforts to reduce the global burden of small vulnerable newborns (SVNs) by scaling up existing preventive interventions must be complemented…
Automated reporting of primaquine dose efficacy, tolerability and safety for Plasmodium vivax malaria using a systematic review and individual patient data meta-analysis
November 14, 2025
Background The antirelapse efficacy of primaquine is related to the total dose administered, whereas the risks of haemolysis and gastrointestinal…